```markdown

---

title: "Invitae Spinout Aris Genomics Closes $142M Series B to Scale Pharmacogenomics Platform"

date: 2026-06-26

category: Funding

excerpt: "Aris Genomics secures $142M Series B to expand its pharmacogenomics platform targeting medication optimization in health systems."

sponsored: false

---

Aris Genomics, a pharmacogenomics company that spun out of Invitae's clinical assets in late 2024, announced today the close of a $142 million Series B funding round led by General Atlantic, with participation from Andreessen Horowitz Bio and returning investors Foresite Capital and OrbiMed. The round brings the company's total raised to just over $210 million and signals continued investor confidence in pharmacogenomics as a cost-reduction lever for health systems managing chronic disease populations.

What Aris Is Building

The company's core offering, PGxPath, is an integrated platform that combines saliva-based germline testing with a clinical decision support layer embedded directly into major EHR systems including Epic and Oracle Health. The platform analyzes variants across more than 60 clinically actionable genes and maps results against a patient's active medication list in real time, flagging gene-drug interactions before a prescription is filled. Aris says PGxPath is currently deployed across 34 health system partners in the United States, covering a combined patient population of approximately 9 million individuals.

CEO Dr. Priya Sundaram, formerly VP of clinical genomics at Invitae, said the new capital will be used primarily to accelerate health system contracting, expand the company's evidence generation team, and pursue additional FDA clearances for its oncology pharmacogenomics modules. The company received 510(k) clearance for its core medication optimization panel in March of this year and is currently pursuing a broader oncology indication that would include actionable variants relevant to chemotherapy toxicity risk.

Why This Round Matters for the Industry

The Aris funding round arrives at a moment when pharmacogenomics is moving from a niche clinical curiosity to a reimbursement-supported standard of care. Several large commercial payers, including UnitedHealthcare and Elevance Health, expanded their coverage policies for multi-gene pharmacogenomics panels in early 2026, covering testing for patients on three or more concurrent medications. That policy shift has materially changed the business case for health system adoption, removing a reimbursement barrier that stalled earlier platform plays in this space.

The round also reflects a broader maturation happening across clinical genomics infrastructure companies. Rather than competing on sequencing itself, a new generation of vendors is stacking value in the interpretation and workflow integration layers, where stickiness is higher and margins are more defensible. Aris Genomics appears well-positioned to be a consolidating platform in that layer as the pharmacogenomics market approaches what analysts at Cowen estimate will be a $4.8 billion addressable market by 2029.

```